RT Journal Article
SR Electronic
T1 Epidemiology and transmission dynamics of COVID-19 in two Indian states
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.14.20153643
DO 10.1101/2020.07.14.20153643
A1 Laxminarayan, Ramanan
A1 Wahl, Brian
A1 Dudala, Shankar Reddy
A1 Gopal, K.
A1 Mohan, Chandra
A1 Neelima, S.
A1 Jawahar Reddy, K. S.
A1 Radhakrishnan, J.
A1 Lewnard, Joseph A.
YR 2020
UL http://medrxiv.org/content/early/2020/07/17/2020.07.14.20153643.abstract
AB Although most COVID-19 cases have occurred in low-resource countries, there is scarce information on the epidemiology of the disease in such settings. Comprehensive SARS-CoV-2 testing and contact-tracing data from the Indian states of Tamil Nadu and Andhra Pradesh reveal stark contrasts from epidemics affecting high-income countries, with 92.1% of cases and 59.7% of deaths occurring among individuals <65 years old. The per-contact risk of infection is 9.0% (95% confidence interval: 7.5-10.5%) in the household and 2.6% (1.6-3.9%) in the community. Superspreading plays a prominent role in transmission, with 5.4% of cases accounting for 80% of infected contacts. The case-fatality ratio is 1.3% (1.0-1.6%), and median time-to-death is 5 days from testing. Primary data are urgently needed from low- and middle-income countries to guide locally-appropriate control measures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJAL received support from the Berkeley Population Center (grant number P2CHD073964 from the National Institute of Child Health & Human Development, National Institutes of Health)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data were obtained through public health surveillance and this work was considered non-human subjects research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAggregate data underlying the analyses are presented in the supplemental tables.